These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33370300)

  • 1. Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya.
    Njomo DW; Kimani BW; Kibe LW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0009012. PubMed ID: 33370300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya.
    Kusi C; Steinmann P; Merten S
    Infect Dis Poverty; 2020 Mar; 9(1):22. PubMed ID: 32114985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Thailand eliminated lymphatic filariasis as a public health problem.
    Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
    Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach.
    Njomo DW; Kibe LW; Kimani BW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008499. PubMed ID: 32936792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment.
    Njenga SM; Kanyi H; Okoyo C; Githinji E; Mwatele C; Matendechero SH; Omondi WP; Gitahi PN; Owaga C; Onsongo JK; Gass K
    PLoS Negl Trop Dis; 2024 Jul; 18(7):e0011942. PubMed ID: 38976718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya.
    Njomo DW; Mukoko DA; Nyamongo NK; Karanja J
    PLoS One; 2014; 9(1):e83413. PubMed ID: 24454703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya.
    Njomo DW; Amuyunzu-Nyamongo M; Magambo JK; Njenga SM
    PLoS One; 2012; 7(11):e48395. PubMed ID: 23185256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.
    Krentel A; Fischer P; Manoempil P; Supali T; Servais G; Rückert P
    Trop Med Int Health; 2006 Nov; 11(11):1731-40. PubMed ID: 17054754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards elimination of Lymphatic Filariasis in Kenya: improving advocacy, communication and social mobilization activities for mass drug administration, a qualitative study.
    Kibe LW; Kimani BW; Okoyo C; Omondi WP; Sultani HM; Njomo DW
    Trop Dis Travel Med Vaccines; 2022 Jun; 8(1):16. PubMed ID: 35668465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana.
    Minetti C; Tettevi EJ; Mechan F; Prada JM; Idun B; Biritwum NK; Osei-Atweneboana MY; Reimer LJ
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006994. PubMed ID: 30608931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are census data accurate for estimating coverage of a lymphatic filariasis MDA campaign? Results of a survey in Sierra Leone.
    Kamara W; Zoerhoff KL; Toubali EH; Hodges MH; Bisanzio D; Chowdhury D; Sonnie M; Magbity E; Samai M; Conteh A; Macarthy F; Baker M; Koroma JB
    PLoS One; 2019; 14(12):e0224422. PubMed ID: 31856176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa.
    Silumbwe A; Zulu JM; Halwindi H; Jacobs C; Zgambo J; Dambe R; Chola M; Chongwe G; Michelo C
    BMC Public Health; 2017 May; 17(1):484. PubMed ID: 28532397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions of the roles, impact, challenges and needs of community drug distributors in the control and elimination of neglected tropical diseases in difficult-to-access communities in Ghana.
    Forson AO; Awuah RB; Mohammed AR; Owusu-Asenso CM; Atakora SB; Akosah-Brempong G; Abdulai A; Sraku IK; Dhikrullahi SB; Attah SK; Afrane YA
    BMC Infect Dis; 2023 Jul; 23(1):460. PubMed ID: 37430222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana.
    Dicko I; Coulibaly YI; Sangaré M; Sarfo B; Nortey PA
    Infect Disord Drug Targets; 2020; 20(2):167-174. PubMed ID: 30727921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
    Lupenza ET; Gasarasi DB; Minzi OM
    PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: The case of Luangwa District, Zambia.
    Silumbwe A; Halwindi H; Zulu JM
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007861. PubMed ID: 31774820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
    Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
    Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling Neglected Tropical Diseases (NTDs) in Haiti: Implementation Strategies and Evidence of Their Success.
    Lemoine JF; Desormeaux AM; Monestime F; Fayette CR; Desir L; Direny AN; Carciunoiu S; Miller L; Knipes A; Lammie P; Smith P; Stockton M; Trofimovich L; Bhandari K; Reithinger R; Crowley K; Ottesen E; Baker M
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0004954. PubMed ID: 27706162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community-directed treatment of lymphatic filariasis in Kenya and its role in the national programmes for elimination of lymphatic filariasis.
    Wamae N; Njenga SM; Kisingu WM; Muthigani PW; Kiiru K
    Afr J Health Sci; 2006; 13(1-2):69-79. PubMed ID: 17348745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.